Trial Profile
A retrospective study evaluating efficacy of nivolumab in patients with clear cell metastatic renal carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 Jun 2018 Results assessing predictors of progressive disease on nivolumab presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 14 Mar 2018 New trial record
- 10 Feb 2018 Results assessing the patterns of disease progression in nivolumab treated metastatic renal cell carcinoma patients presented at the 2018 Genitourinary Cancers Symposium